Supplementary Material for: A Unique Case Report of Infant-Type Hemispheric Glioma (Gliosarcoma Subtype) with <b><i>TPR</i></b>-<b><i>NTRK1</i></b> Fusion Treated with Larotrectinib

Herein, we present a rare case of a nine-month-old boy diagnosed with infant-type hemispheric glioma (gliosarcoma subtype) at the left frontal lobe. Following subtotal resection, the patient started chemotherapy with the BABY POG protocol. We describe the clinical diagnosis, histological characteristics, radiological features, molecular aspects, and management of this tumor. A comprehensive molecular analysis on the tumor tissue showed a <i>TPR-NTRK1</i> gene fusion. The patient was treated with a TRK inhibitor, larotrectinib, and exhibited a stable disease with residual lesion following 8 months of target therapy. The present study is the first report of an infantile gliosarcoma harboring <i>NTRK1</i> rearrangement treated with larotrectinib.

本研究报告1例罕见病例：一名9月龄男性患儿，于左侧额叶确诊为婴儿型半球性胶质瘤（胶质肉瘤亚型）。患儿接受次全切除术后，采用BABY POG方案进行化疗。本文详述该肿瘤的临床诊断、组织学特征、影像学表现、分子生物学特点及诊疗策略。对肿瘤组织开展的全面分子分析显示存在TPR-NTRK1基因融合。患儿接受TRK抑制剂（TRK inhibitor）拉罗替尼（larotrectinib）治疗，经8个月靶向治疗后，仍存在病灶残留且病情维持稳定。本研究为全球首项报道采用拉罗替尼治疗携带NTRK1重排的婴儿型胶质肉瘤的病例报告。

搜集汇总

背景与挑战

背景概述

该数据集是一个罕见婴儿型半球胶质瘤（胶质肉瘤亚型）病例的补充材料，详细描述了9个月大男婴的临床诊断、分子分析显示TPR-NTRK1基因融合，以及使用Larotrectinib靶向治疗后的稳定病情。作为首个报告NTRK1重排婴儿胶质肉瘤使用Larotrectinib治疗的案例，它突出了靶向疗法在罕见儿科肿瘤中的应用价值。